Apollomics Inc., a biopharmaceutical company, has addressed a comment from the United States Securities and Exchange Commission (SEC) regarding its Registration Statement on Form F-3, initially filed on April 1, 2024. The SEC's Division of Corporation Finance had issued a comment letter on April 15, 2024, seeking clarification on a discrepancy in the company's filing. The issue pertained to the residency of the board of directors, with the SEC noting conflicting information about the location of two directors. Apollomics has since amended the Registration Statement to reconcile the inconsistencies, confirming that all board members reside outside of China. The amendment was filed via EDGAR as Amendment No. 1, reflecting the company's response to the SEC's inquiry. White & Case LLP, representing Apollomics, has communicated the company's response and is open for further contact regarding the matter.

Apollomics Inc., a biopharmaceutical company, has addressed a comment from the United States Securities and Exchange Commission (SEC) regarding its Registration Statement on Form F-3, initially filed on April 1, 2024. The SEC's Division of Corporation Finance had issued a comment letter on April 15, 2024, seeking clarification on a discrepancy in the company's filing. The issue pertained to the residency of the board of directors, with the SEC noting conflicting information about the location of two directors. Apollomics has since amended the Registration Statement to reconcile the inconsistencies, confirming that all board members reside outside of China. The amendment was filed via EDGAR as Amendment No. 1, reflecting the company's response to the SEC's inquiry. White & Case LLP, representing Apollomics, has communicated the company's response and is open for further contact regarding the matter.